Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

BACKGROUND: The potassium‐competitive acid blocker vonoprazan (VPZ) has potent acid‐inhibitory effects and may offer clinical advantages over conventional therapy for acid‐related disorders. AIM: To investigate the efficacy and safety of VPZ in patients with erosive oesophagitis (EO). METHODS: In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashida, K., Sakurai, Y., Nishimura, A., Kudou, K., Hiramatsu, N., Umegaki, E., Iwakiri, K., Chiba, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Randomised Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014135/
https://www.ncbi.nlm.nih.gov/pubmed/26201312
http://dx.doi.org/10.1111/apt.13331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014135/
https://www.ncbi.nlm.nih.gov/pubmed/26201312
http://dx.doi.org/10.1111/apt.13331

Ejemplares similares